WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Erigbali P. P.*, Joffa P. P. K., Kiridi E. G., Pughikumo D. T., Potts-Johnson G., Bringide V. and Edo P.

ABSTRACT

This research explored for potential benefit of 2, 5-dibenzodioxoylmethyledenecyclopentan-1-one (A10) and 2,5-diphenylmethylidenepentan-1-one (A9) in treatment of pain; since traditional analgesics pose risks of addictionand adverse effects. This study implored preclinical experimentation involving hot plate and tail flick tests for theneurobehaviour - pain. Further in the methods was induction of pain in mice groups, following treatment regimenswith A9, A10, distilled water (dw) and tramadol (tm). Impact of these on pain threshold was assessed by latencyperiods for nociceptive responses in the mice. Statistical analysis using one-way ANOVA followed by Dunnett’stest in comparing treatment groups evaluated their analgesic benefit. Findings reveal significant (p<0.0001)increases in pain threshold for A10 and tm treated animals, than dw (control). Thus, indicating potential analgesiceffect of A10. Analysis alongside standard drug highlights a potential preferential option of A10 in acute painmanagement. Furtherance of investigation is recommended for safety profiling as this contributes to advancingunderstanding of emerging analgesic interventions and underscores the need for innovative approaches in painpharmacotherapy.

[Full Text Article] [Download Certificate]